Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 46 of 46 entries
Sorted by: Best Match Show Resources per page
Emerging therapies for heart failure.

Expert opinion on emerging drugs

Rudolph AE, McMahon EG.
PMID: 15989548
Expert Opin Emerg Drugs. 2002 Oct;7(2):247-58. doi: 10.1517/14728214.7.2.247.

Although multiple advancements have been made in the treatment of heart failure (HF), mortality rates remain alarmingly high. The accepted arsenal of therapeutics includes a diuretic, digitalis, a beta-blocking agent and an inhibitor of the renin-angiotensin-aldosterone system. Despite the...

Cite
Rudolph AE, McMahon EG. Emerging therapies for heart failure. Expert Opin Emerg Drugs. 2002;7(2):247-58doi: 10.1517/14728214.7.2.247.
Rudolph, A. E., & McMahon, E. G. (2002). Emerging therapies for heart failure. Expert opinion on emerging drugs, 7(2), 247-58. https://doi.org/10.1517/14728214.7.2.247
Rudolph, Amy E, and McMahon, Ellen G. "Emerging therapies for heart failure." Expert opinion on emerging drugs vol. 7,2 (2002): 247-58. doi: https://doi.org/10.1517/14728214.7.2.247
Rudolph AE, McMahon EG. Emerging therapies for heart failure. Expert Opin Emerg Drugs. 2002 Oct;7(2):247-58. doi: 10.1517/14728214.7.2.247. PMID: 15989548.
Copy Download .nbib Format: NLM
Matrix metalloproteinase inhibitors: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Watson SA, Tierney G.
PMID: 18020568
BioDrugs. 1998 Apr;9(4):325-35. doi: 10.2165/00063030-199809040-00005.

The matrix metalloproteinases (MMPs) are a family of closely related, zinc-dependent proteolytic enzymes. Collectively, they are capable of degrading all the components of the extracellular matrix and as such are involved in a number of physiological and pathological processes....

Cite
Watson SA, Tierney G. Matrix metalloproteinase inhibitors: a review. BioDrugs. 1998;9(4):325-35doi: 10.2165/00063030-199809040-00005.
Watson, S. A., & Tierney, G. (1998). Matrix metalloproteinase inhibitors: a review. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 9(4), 325-35. https://doi.org/10.2165/00063030-199809040-00005
Watson, S A, and Tierney, G. "Matrix metalloproteinase inhibitors: a review." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 9,4 (1998): 325-35. doi: https://doi.org/10.2165/00063030-199809040-00005
Watson SA, Tierney G. Matrix metalloproteinase inhibitors: a review. BioDrugs. 1998 Apr;9(4):325-35. doi: 10.2165/00063030-199809040-00005. PMID: 18020568.
Copy Download .nbib Format: NLM
Evaluation of indomethacin as matrix metalloproteases inhibitor in human dentin.

Journal of conservative dentistry : JCD

Shailendra M, Bhandari S, Kulkarni S, Janavathi K, Ghatole K.
PMID: 33088073
J Conserv Dent. 2019 Nov-Dec;22(6):598-601. doi: 10.4103/JCD.JCD_236_19. Epub 2020 Aug 20.

OBJECTIVE: The objective was to determine a new experimental material, indomethacin's inhibitory effect on the enzymatic activity of dentin collagen.MATERIALS AND METHODS: Fifteen freshly extracted teeth were collected and stored at 4°C until use. Enamel, roots, and remnant pulp...

Cite
Shailendra M, Bhandari S, Kulkarni S, et al. Evaluation of indomethacin as matrix metalloproteases inhibitor in human dentin. J Conserv Dent. 2020;22(6):598-601doi: 10.4103/JCD.JCD_236_19.
Shailendra, M., Bhandari, S., Kulkarni, S., Janavathi, K., & Ghatole, K. (2019). Evaluation of indomethacin as matrix metalloproteases inhibitor in human dentin. Journal of conservative dentistry : JCD, 22(6), 598-601. https://doi.org/10.4103/JCD.JCD_236_19
Shailendra, Mashalkar, et al. "Evaluation of indomethacin as matrix metalloproteases inhibitor in human dentin." Journal of conservative dentistry : JCD vol. 22,6 (2019): 598-601. doi: https://doi.org/10.4103/JCD.JCD_236_19
Shailendra M, Bhandari S, Kulkarni S, Janavathi K, Ghatole K. Evaluation of indomethacin as matrix metalloproteases inhibitor in human dentin. J Conserv Dent. 2019 Nov-Dec;22(6):598-601. doi: 10.4103/JCD.JCD_236_19. Epub 2020 Aug 20. PMID: 33088073; PMCID: PMC7542069.
Copy Download .nbib Format: NLM
Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy.

Pharmaceuticals (Basel, Switzerland)

Laghezza A, Piemontese L, Brunetti L, Caradonna A, Agamennone M, Di Pizio A, Pochetti G, Montanari R, Capelli D, Tauro M, Loiodice F, Tortorella P.
PMID: 32492898
Pharmaceuticals (Basel). 2020 Jun 01;13(6). doi: 10.3390/ph13060113.

Matrix metalloproteinases (MMPs) are a family of enzymes involved at different stages of cancer progression and metastasis. We previously identified a novel class of bisphosphonic inhibitors, selective for MMPs crucial for bone remodeling, such as MMP-2. Due to the...

Cite
Laghezza A, Piemontese L, Brunetti L, et al. Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy. Pharmaceuticals (Basel). 2020;13(6)doi: 10.3390/ph13060113.
Laghezza, A., Piemontese, L., Brunetti, L., Caradonna, A., Agamennone, M., Di Pizio, A., Pochetti, G., Montanari, R., Capelli, D., Tauro, M., Loiodice, F., & Tortorella, P. (2020). Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy. Pharmaceuticals (Basel, Switzerland), 13(6), . https://doi.org/10.3390/ph13060113
Laghezza, Antonio, et al. "Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy." Pharmaceuticals (Basel, Switzerland) vol. 13,6 (2020). doi: https://doi.org/10.3390/ph13060113
Laghezza A, Piemontese L, Brunetti L, Caradonna A, Agamennone M, Di Pizio A, Pochetti G, Montanari R, Capelli D, Tauro M, Loiodice F, Tortorella P. Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy. Pharmaceuticals (Basel). 2020 Jun 01;13(6). doi: 10.3390/ph13060113. PMID: 32492898; PMCID: PMC7344628.
Copy Download .nbib Format: NLM
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.

Biomolecules & therapeutics

Lee EJ, Moon PG, Baek MC, Kim HS.
PMID: 25414771
Biomol Ther (Seoul). 2014 Sep;22(5):414-9. doi: 10.4062/biomolther.2014.099. Epub 2014 Sep 30.

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that regulate cell-matrix composition and are also involved in processing various bioactive molecules such as cell-surface receptors, chemokines, and cytokines. Our group recently reported that MMP-3, -8, and -9 are upregulated during microglial...

Cite
Lee EJ, Moon PG, Baek MC, et al. Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity. Biomol Ther (Seoul). 2014;22(5):414-9doi: 10.4062/biomolther.2014.099.
Lee, E. J., Moon, P. G., Baek, M. C., & Kim, H. S. (2014). Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity. Biomolecules & therapeutics, 22(5), 414-9. https://doi.org/10.4062/biomolther.2014.099
Lee, Eun-Jung, et al. "Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity." Biomolecules & therapeutics vol. 22,5 (2014): 414-9. doi: https://doi.org/10.4062/biomolther.2014.099
Lee EJ, Moon PG, Baek MC, Kim HS. Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity. Biomol Ther (Seoul). 2014 Sep;22(5):414-9. doi: 10.4062/biomolther.2014.099. Epub 2014 Sep 30. PMID: 25414771; PMCID: PMC4201218.
Copy Download .nbib Format: NLM
Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab.

Case reports in ophthalmology

Britton AK, Crayford BB.
PMID: 33442379
Case Rep Ophthalmol. 2020 Dec 07;11(3):652-657. doi: 10.1159/000510114. eCollection 2020.

Corneal neovascularization (CNV) has a variety of causes and threatens corneal clarity, thus optimal visual acuity. Conventional medical management includes topical steroids and matrix metalloproteinase inhibitors like doxycycline. Anti-vascular endothelial growth factor (anti-VEGF) agents have demonstrated promise but remain...

Cite
Britton AK, Crayford BB. Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab. Case Rep Ophthalmol. 2020;11(3):652-657doi: 10.1159/000510114.
Britton, A. K., & Crayford, B. B. (2020). Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab. Case reports in ophthalmology, 11(3), 652-657. https://doi.org/10.1159/000510114
Britton, Anna Krystyna, and Crayford, Basil Bamford. "Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab." Case reports in ophthalmology vol. 11,3 (2020): 652-657. doi: https://doi.org/10.1159/000510114
Britton AK, Crayford BB. Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab. Case Rep Ophthalmol. 2020 Dec 07;11(3):652-657. doi: 10.1159/000510114. eCollection 2020. PMID: 33442379; PMCID: PMC7772892.
Copy Download .nbib Format: NLM
Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.

Future medicinal chemistry

Lin H, Xu P, Huang M.
PMID: 34779649
Future Med Chem. 2022 Jan;14(1):35-51. doi: 10.4155/fmc-2021-0246. Epub 2021 Nov 15.

Protease inhibitors are of considerable interest as anticancer agents. Matrix metalloproteinases (MMPs) were the earliest type of proteases considered as anticancer targets. The developments of MMP inhibitors (MMPIs) by pharmaceutical companies can be dated from the early 1980s. Thus...

Cite
Lin H, Xu P, Huang M. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future Med Chem. 2021;14(1):35-51doi: 10.4155/fmc-2021-0246.
Lin, H., Xu, P., & Huang, M. (2022). Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future medicinal chemistry, 14(1), 35-51. https://doi.org/10.4155/fmc-2021-0246
Lin, Haili, et al. "Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments." Future medicinal chemistry vol. 14,1 (2022): 35-51. doi: https://doi.org/10.4155/fmc-2021-0246
Lin H, Xu P, Huang M. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future Med Chem. 2022 Jan;14(1):35-51. doi: 10.4155/fmc-2021-0246. Epub 2021 Nov 15. PMID: 34779649.
Copy Download .nbib Format: NLM
Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage.

Neurocritical care

Kearns KN, Ironside N, Park MS, Worrall BB, Southerland AM, Chen CJ, Ding D.
PMID: 34341912
Neurocrit Care. 2021 Aug 02; doi: 10.1007/s12028-021-01311-3. Epub 2021 Aug 02.

Patients who survive the initial ictus of spontaneous intracerebral hemorrhage (ICH) remain vulnerable to subsequent injury of the perilesional parenchyma by molecular and cellular responses to the hematoma. Secondary brain injury after ICH, which contributes to long-term functional impairment...

Cite
Kearns KN, Ironside N, Park MS, et al. Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2021;doi: 10.1007/s12028-021-01311-3.
Kearns, K. N., Ironside, N., Park, M. S., Worrall, B. B., Southerland, A. M., Chen, C. J., & Ding, D. (2021). Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocritical care, . https://doi.org/10.1007/s12028-021-01311-3
Kearns, Kathryn N, et al. "Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage." Neurocritical care vol. (2021). doi: https://doi.org/10.1007/s12028-021-01311-3
Kearns KN, Ironside N, Park MS, Worrall BB, Southerland AM, Chen CJ, Ding D. Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2021 Aug 02; doi: 10.1007/s12028-021-01311-3. Epub 2021 Aug 02. PMID: 34341912.
Copy Download .nbib Format: NLM
Towards Optimized Bioavailability of .

Molecular imaging and biology

Honold L, Austrup M, Faust A, Konken CP, Schwegmann K, Zinnhardt B, Daniliuc CG, Haufe G, Schäfers M, Kopka K, Hermann S.
PMID: 34750717
Mol Imaging Biol. 2021 Nov 08; doi: 10.1007/s11307-021-01668-z. Epub 2021 Nov 08.

INTRODUCTION: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respect to the...

Cite
Honold L, Austrup M, Faust A, et al. Towards Optimized Bioavailability of . Mol Imaging Biol. 2021;doi: 10.1007/s11307-021-01668-z.
Honold, L., Austrup, M., Faust, A., Konken, C. P., Schwegmann, K., Zinnhardt, B., Daniliuc, C. G., Haufe, G., Schäfers, M., Kopka, K., & Hermann, S. (2021). Towards Optimized Bioavailability of . Molecular imaging and biology, . https://doi.org/10.1007/s11307-021-01668-z
Honold, Lisa, et al. "Towards Optimized Bioavailability of ." Molecular imaging and biology vol. (2021). doi: https://doi.org/10.1007/s11307-021-01668-z
Honold L, Austrup M, Faust A, Konken CP, Schwegmann K, Zinnhardt B, Daniliuc CG, Haufe G, Schäfers M, Kopka K, Hermann S. Towards Optimized Bioavailability of . Mol Imaging Biol. 2021 Nov 08; doi: 10.1007/s11307-021-01668-z. Epub 2021 Nov 08. PMID: 34750717.
Copy Download .nbib Format: NLM
Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease.

Journal of pharmacy & bioallied sciences

Honibald EN, Mathew S, Padmanaban J, Sundaram E, Ramamoorthy RD.
PMID: 23066302
J Pharm Bioallied Sci. 2012 Aug;4:S417-21. doi: 10.4103/0975-7406.100315.

Matrix metalloproteinases (MMPs) form a group of more than 20 zinc-dependent enzymes that are crucial in the degradation of the main components in the extracellular matrix, and thereby play important roles in cell migration, wound healing, and tissue remodeling....

Cite
Honibald EN, Mathew S, Padmanaban J, et al. Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease. J Pharm Bioallied Sci. 2012;4:S417-21doi: 10.4103/0975-7406.100315.
Honibald, E. N., Mathew, S., Padmanaban, J., Sundaram, E., & Ramamoorthy, R. D. (2012). Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease. Journal of pharmacy & bioallied sciences, 4S417-21. https://doi.org/10.4103/0975-7406.100315
Honibald, Esther Nalini, et al. "Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease." Journal of pharmacy & bioallied sciences vol. 4 (2012): S417-21. doi: https://doi.org/10.4103/0975-7406.100315
Honibald EN, Mathew S, Padmanaban J, Sundaram E, Ramamoorthy RD. Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease. J Pharm Bioallied Sci. 2012 Aug;4:S417-21. doi: 10.4103/0975-7406.100315. PMID: 23066302; PMCID: PMC3467883.
Copy Download .nbib Format: NLM
Showing 37 to 46 of 46 entries